BIIB
Drug Manufacturers - General · Healthcare
CEO, Board Member
2022-01-01–present
Board Member
Biogen Inc. (BIIB)Equibles does not estimate personal net worth.
Get an email with a short summary when Biogen Inc. publishes a filing, an earnings call transcript or a press release.
Get BIIB alertsChristopher Viehbacher is recorded as Board Member at Biogen Inc. (BIIB) since January 1, 2022 and CEO at Biogen Inc. (BIIB). The proxy statement of Biogen Inc. reports total compensation of $23,646,004 for Christopher Viehbacher in fiscal 2025, including a base salary of $1,727,885. Disclosed compensation is on record for 4 fiscal years. Christopher Viehbacher has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Biogen Inc. on July 29, 2026. Biogen Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Biogen Inc. includes Christopher A. Viehbacher (CEO and Board Member), Caroline D. Dorsa (Chairman), Michael R. McDonnell (CFO) and 7 others.
“And just the U.S. is actually one of the last countries to launch actually unusually. So Japan, where we launched earlier as in Europe, that's where actually we're seeing, particularly in Germany, seeing a reversal of the trend of switching to oral therapy and some trending back.”
“So we've had a very strong start to the year. And, you know, I was thinking about where we have been as a company. In 2023, we had just completed four years of declining revenue and profit.”
“We finished the year strongly with a very good fourth quarter, and I think finished the year in a very satisfactory manner.”
“I've got my current head of IR and my prior head of IR from Sanofi here with me to make sure I don't screw up. All right, so exciting year at Biogen. You know, we've been on a long journey.”
“I believe we've achieved a very strong third quarter. I am particularly pleased to report a 67% year-on-year growth in our launch products during this quarter. These launch products have more than compensated for the MS decline on a year-to-date basis.”
2022-01-01–present
BIIB
Drug Manufacturers - General · Healthcare
CEO, Board Member
2022-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biogen Inc. (BIIB) | President and Chief Executive Officer | $1,727,885 | $23,646,004 |
| 2024 | Biogen Inc. (BIIB) | President and CEO | $1,600,000 | $24,166,665 |
| 2023 | Biogen Inc. (BIIB) | President and CEO | $1,600,000 | $4,069,913 |
| 2022 | Biogen Inc. (BIIB) | President and CEO | $153,846 | $30,488,593 |